BidaskClub downgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a sell rating in a research note published on Friday, March 9th.
A number of other research firms also recently weighed in on LNTH. Zacks Investment Research downgraded Lantheus from a hold rating to a strong sell rating in a research report on Friday, March 2nd. ValuEngine downgraded Lantheus from a buy rating to a hold rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $24.75.
Lantheus (NASDAQ LNTH) remained flat at $$16.20 during trading on Friday. The company’s stock had a trading volume of 528,148 shares, compared to its average volume of 490,719. Lantheus has a one year low of $10.65 and a one year high of $24.45. The company has a debt-to-equity ratio of 11.40, a current ratio of 3.16 and a quick ratio of 2.60. The stock has a market capitalization of $613.34, a P/E ratio of 5.14, a price-to-earnings-growth ratio of 1.29 and a beta of 1.56.
Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Monday, February 26th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.20 by ($0.08). The business had revenue of $81.24 million for the quarter, compared to the consensus estimate of $78.57 million. Lantheus had a net margin of 37.23% and a negative return on equity of 68.13%. Lantheus’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.18 EPS. research analysts anticipate that Lantheus will post 1.04 earnings per share for the current year.
In other Lantheus news, insider Michael P. Duffy sold 11,492 shares of the business’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $16.60, for a total transaction of $190,767.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO John W. Crowley sold 3,866 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $23.52, for a total transaction of $90,928.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,709 shares of company stock worth $839,135. Insiders own 2.30% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Lantheus by 87.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after buying an additional 689,954 shares during the period. State Street Corp boosted its holdings in shares of Lantheus by 3,932.8% during the 2nd quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock valued at $10,891,000 after purchasing an additional 601,714 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Lantheus by 73.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 911,311 shares of the medical equipment provider’s stock valued at $16,221,000 after purchasing an additional 386,771 shares during the last quarter. LSV Asset Management boosted its holdings in shares of Lantheus by 57.5% during the 4th quarter. LSV Asset Management now owns 953,906 shares of the medical equipment provider’s stock valued at $19,507,000 after purchasing an additional 348,298 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Lantheus during the 4th quarter valued at about $6,552,000. Hedge funds and other institutional investors own 90.46% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/17/bidaskclub-lowers-lantheus-lnth-to-sell.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.